An experimental evaluation of patient decision aid design to communicate the effects of medications on the rate of progression of structural joint damage in rheumatoid arthritis.

OBJECTIVE To explore how effectively information presentation formats used in a patient decision aid communicated the ability of a disease modifying anti-rheumatic drug to slow the rate of progression of rheumatoid arthritis related structural joint damage (SJD). METHODS 91 first year psychology students and 91 RA patients participated in a prospective randomized, single blind, factorial experimental design evaluating the effect of four information formats on: satisfaction with risk communication, verbatim and gist recall of a hypothetical anti-rheumatic drug's ability to slow the rate of progression of SJD. RESULTS Both groups underestimated the hypothetical drug's ability to slow SJD. Formats that supported the narrative statement with a reinforcing graphic element resulted in recall closer to the true value. Comparison of the results from testing of RA patients and college students were remarkably similar across formats. CONCLUSION Rate of progression as communicated by narrative statement plus a graphic element (i.e. speedometer metaphor or pictograph) aided recall better than a narrative statement alone. Our results suggest that testing decision aid components with non-patients may provide data generalizable to patient populations. PRACTICE IMPLICATIONS Graphics must be used carefully in patient decision aids as they can enhance recall, but may also introduce unintended recall bias.

[1]  Miranda R. Goode,et al.  The Psychological Consequences of Money , 2006, Science.

[2]  K. Vohs,et al.  How Emotion Shapes Behavior: Feedback, Anticipation, and Reflection, Rather Than Direct Causation , 2007, Personality and social psychology review : an official journal of the Society for Personality and Social Psychology, Inc.

[3]  Glyn Elwyn,et al.  The development of COMRADE--a patient-based outcome measure to evaluate the effectiveness of risk communication and treatment decision making in consultations. , 2003, Patient education and counseling.

[4]  V. Wong,et al.  Continuation of Low-Dose Aspirin Therapy in Peptic Ulcer Bleeding , 2010, Annals of Internal Medicine.

[5]  B. Hernández-Cruz,et al.  Adalimumab for treating rheumatoid arthritis. , 2005, The Journal of rheumatology.

[6]  C. K. Mertz,et al.  Less Is More in Presenting Quality Information to Consumers , 2007, Medical care research and review : MCRR.

[7]  Richard W. Martin,et al.  A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. , 2000, The New England journal of medicine.

[8]  Steven Woloshin,et al.  Using a Drug Facts Box to Communicate Drug Benefits and Harms Two Randomized Trials , 2009, Annals of Internal Medicine.

[9]  P. Ubel Is Information Always a Good Thing?: Helping Patients Make “Good” Decisions , 2002, Medical care.

[10]  Susan Kemper,et al.  The use of illustration to improve older adults' comprehension of health-related information: is it helpful? , 2009, Patient education and counseling.

[11]  A. Tversky,et al.  Choices, Values, and Frames , 2000 .

[12]  L. Fraenkel,et al.  Understanding why rheumatoid arthritis patient treatment preferences differ by race. , 2009, Arthritis and rheumatism.

[13]  R. Horne,et al.  Prediction of nonspecific side effects in rheumatoid arthritis patients by beliefs about medicines , 2010, Arthritis care & research.

[14]  J. Singh,et al.  Anakinra for rheumatoid arthritis. , 2009, The Cochrane database of systematic reviews.

[15]  H. Bekker,et al.  The loss of reason in patient decision aid research: do checklists damage the quality of informed choice interventions? , 2010, Patient education and counseling.

[16]  A. Tversky,et al.  Prospect Theory : An Analysis of Decision under Risk Author ( s ) : , 2007 .

[17]  Mark Conner,et al.  Does narrative information bias individual's decision making? A systematic review. , 2008, Social science & medicine.

[18]  D. Moher,et al.  CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials , 2010, Journal of clinical epidemiology.

[19]  Lisa M. Schwartz,et al.  The Effectiveness of a Primer to Help People Understand Risk , 2007, Annals of Internal Medicine.

[20]  Sarah M. Greene,et al.  Testing whether decision aids introduce cognitive biases: results of a randomized trial. , 2010, Patient education and counseling.

[21]  P. Ubel,et al.  Communicating side effect risks in a tamoxifen prophylaxis decision aid: the debiasing influence of pictographs. , 2008, Patient education and counseling.

[22]  F. Guillemin,et al.  Choice of second-line disease-modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: a decision tree for clinical practice based on rheumatologists' preferences. , 2009, Arthritis and rheumatism.

[23]  B. Rimer,et al.  General Performance on a Numeracy Scale among Highly Educated Samples , 2001, Medical decision making : an international journal of the Society for Medical Decision Making.

[24]  Gerd Gigerenzer,et al.  Natural Frequencies Help Older Adults and People with Low Numeracy to Evaluate Medical Screening Tests , 2009, Medical decision making : an international journal of the Society for Medical Decision Making.

[25]  V. Reyna,et al.  A Theory of Medical Decision Making and Health: Fuzzy Trace Theory , 2008, Medical decision making : an international journal of the Society for Medical Decision Making.

[26]  Eric J. Johnson,et al.  The adaptive decision maker , 1993 .

[27]  G. Chapman The Psychology of Medical Decision Making , 2008 .

[28]  L. Trupin,et al.  Receipt of disease-modifying antirheumatic drugs among patients with rheumatoid arthritis in Medicare managed care plans. , 2011, Journal of the American Medical Association (JAMA).

[29]  V. Reyna CURRENT DIRECTIONS IN PSYCHOLOGICAL SCIENCE How People Make Decisions That Involve Risk A Dual-Processes Approach , 2022 .

[30]  K. Lohr,et al.  Systematic Review: Comparative Effectiveness and Harms of Disease-Modifying Medications for Rheumatoid Arthritis , 2008, Annals of Internal Medicine.

[31]  G Gigerenzer,et al.  The Psychology of Good Judgment , 1996, Medical decision making : an international journal of the Society for Medical Decision Making.

[32]  G. Gigerenzer,et al.  Using icon arrays to communicate medical risks: overcoming low numeracy. , 2009, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.

[33]  D. Moher,et al.  CONSORT 2010 Statement: updated guidelines for reporting parallel group randomized trials , 2010, Obstetrics and gynecology.

[34]  G. Elwyn,et al.  One hundred years ago: Should milk be boiled? , 2002, BMJ : British Medical Journal.

[35]  P. Tugwell,et al.  Infliximab for the treatment of rheumatoid arthritis. , 2002, The Cochrane database of systematic reviews.

[36]  Angela Fagerlin,et al.  Screening experiments and the use of fractional factorial designs in behavioral intervention research. , 2008, American journal of public health.

[37]  R. Stein,et al.  The Ophthalmic Assistant: A Guide for Ophthalmic Medical Personnel , 1971 .

[38]  V. Strand,et al.  Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. , 2000, Arthritis and rheumatism.

[39]  M. Lotz,et al.  Autophagy is a protective mechanism in normal cartilage, and its aging-related loss is linked with cell death and osteoarthritis. , 2010, Arthritis and rheumatism.